Document is current
Any future updates will be listed below
-
Authors
Denimal, Damien
Bergas, Victoria
Pais-de-Barros, Jean-Paul
Simoneau, Isabelle
Demizieux, Laurent
Passilly-Degrace, Patricia
Bouillet, Benjamin
Petit, Jean-Michel
Rouland, Alexia
Bataille, Amandine
Duvillard, Laurence
Vergès, Bruno
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02721888 at ClinicalTrials.govDocuments that mention this clinical trial
Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes
https://doi.org/10.1186/s12933-023-01845-0
Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression (Results)
https://doi.org/10.2337/dc20-1843
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
https://doi.org/10.1136/gutjnl-2019-319104
- License Information
-
More Information
Article History
Received: 23 February 2023
Accepted: 29 April 2023
First Online: 4 May 2023
Declarations
:
: The study complies with the Declaration of Helsinki and was approved by the our regional ethics committee.
: Not applicable.
: The authors’ employer (University Hospital of Dijon, France) received funding from Novo Nordisk for this study. Novo Nordisk had no role in collection, analysis, and interpretation of data, in writing the paper, and in the decision to submit the paper for publication. Otherwise, no potential competing interests relevant to this article are reported.
